Boston Scientific Posts Quarterly Profit of $582 Million
The medical device company reported $5.14 billion in revenue for the third quarter of 2026.
Updated on Oct. 28, 2026 in Public Companies
Live Poll
Do you trust the recent performance of large medical device manufacturers as a sign of stability?
Boston Scientific announced a profit of $582 million for the third quarter of 2026, reaching $5.14 billion in total quarterly revenue. The company posted earnings of 40 cents per share, or 73 cents per share when adjusted for non-recurring and amortization costs.
Why it matters
These financial results provide insight into the company's performance amid a challenging period for its equity value. The report details the firm's current fiscal health while outlining expectations for the remainder of the year.
Boston Scientific recorded earnings of 40 cents per share, which rises to 73 cents on an adjusted basis. The company projects earnings between 77 and 79 cents per share for the fourth quarter.
The players
Boston Scientific
This is a global medical technology company based in Marlborough, Massachusetts, that develops devices for use in interventional medical specialties.
The details
Boston Scientific, headquartered in Marlborough, Massachusetts, calculated its adjusted earnings by accounting for amortization and various non-recurring costs. Management issued guidance for full-year earnings, targeting a range of $3.16 to $3.18 per share.
Timeline
The third quarter of 2026 served as the reporting period for these financial results.
The company published its financial report in October 2026.
The current fiscal quarter is scheduled to conclude in December 2026.
Market Landscape
Boston Scientific's stock performance shows a significant divergence from the broader market, with a 54% year-to-date decline compared to the 13% climb of the S&P 500 index. This underperformance highlights the company's struggle to maintain valuation relative to major market benchmarks.
While the profit report provides financial clarity for the organization, the ongoing stock price decline of 57% over the last 12 months reflects significant volatility for investors. Retail shareholders may see these results as a key signal when re-evaluating their positions in the firm.
The takeaway
The company's guidance suggests a path toward consistent annual earnings despite recent stock market headwinds. Investors should monitor the upcoming December quarter end to see if the firm meets its projected earnings targets.
Further reading
For more on how major organizations manage financial cycles, visit the Public Companies section.
Live Poll
Do you trust the recent performance of large medical device manufacturers as a sign of stability?
